Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 4136309

Next Previous
Drug Profile

PF 4136309

Alternative Names: INCB 8761; PF-04136309; PF-4136309

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Analgesics; Antineoplastics
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatic fibrosis; Pain; Pancreatic cancer

Most Recent Events

  • 10 May 2018 Discontinued - Phase-I/II for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in USA (PO)
  • 01 May 2018 Discontinued - Phase-I for Pancreatic cancer (In volunteers) in Belgium (PO)
  • 30 Jan 2018 PF 4136309 receives Orphan Drug status for Pancreatic cancer in USA before January 2018 (Pfizer pipeline, February 2018)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top